| Entry |
|
|---|
| Name |
Rituximab and hyaluronidase;
Rituxan hycela (TN) |
|---|
| Product |
|
|---|
| Component |
Rituximab [DR: D02994], Hyaluronidase (human recombinant) [DR: D06604]
|
|---|
| Remark |
|
|---|
| Efficacy |
Antineoplastic |
|---|
| Disease |
Follicular lymphoma [DS: H01613] Diffuse large B-cell lymphoma [DS: H02434] Chronic lymphocytic leukemia [DS: H00005] |
|---|
| Type |
Monoclonal antibody, combination |
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FA CD20 (Clusters of Differentiation 20) inhibitors
L01FA01 Rituximab
D11393 Rituximab and hyaluronidase <US>
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Anti-CD20 Antibodies
Hyaluronidase/ Rituximab
D11393 Rituximab and hyaluronidase
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
